Safety and Effectiveness of eGERD Device to Reduce Gastroesophageal Reflux Disease (GERD) Symptoms
Key facts
- Who runs it
- Gerd Care Medical Ltd
- Where
- Chicago, United StatesSee the siteAlso in 1 other country, 4 sites
- Trial code
- Status
- Recruiting
- People taking part
- 84 people, planned
- Started
- 15 Sept 2024
- Expected to end
- Apr 2027
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- eGERD device
- eGERD_Sham
- Record updated
- 23 June 2026
Who can take part
- Age
- 22 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 33 criteriaShow less
Who can take part
- Male or female, aged 22 - 75
- Has been typically suffering from at least three heartburn and/or regurgitation episodes per week during the past three months
- Undergone a wireless (Bravo) pH monitoring test during the past 24 months prior to enrollment into the current study, following a 7-day (min.) off-PPI period, with AET ≥6% (as defined in section 7.2) in at least 2 monitoring days AND when averaged over all monitoring days of the test; or, in the absence of such testing, has been determined by the Principal Investigator (PI), based on a detailed anamnesis and with written agreement from the Medical Director, to have gastroesophageal reflux disease (GERD) other than functional GERD; or Undergone a catheter-based pH monitoring test during the past 24 months prior to enrollment into the current study, following a 7-day (min.) off-PPI period, with AET ≥6% (as defined in section 7.2); or, in the absence of such testing, has been determined by the Principal Investigator (PI), based on a detailed anamnesis and with written agreement from the Medical Director, to have gastroesophageal reflux disease (GERD) other than functional GERD
- Able and willing to give informed consent for participation in the study and to comply with all study requirements, including operating the smartphone application
- Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study
Who cannot take part
- Previously undergoing gastric or esophageal surgery
- Active peptic ulcer disease or symptomatic helicobacter
- History of suspected or confirmed esophageal or gastric cancer
- History of any other malignancy in the last 2 years
- Severe cardiac conditions such as cardiac arrhythmia or ischemia or cardiac pacemaker / defibrillator
- Known allergy to the device's adhesives/patches
- Severe pulmonary diseases
- History of significant multisystem diseases (e.g. kidney failure, liver failure)
- Known autoimmune or a connective tissue disorder (e.g. scleroderma, CREST-syndrome, Sjogren's Syndrome), requiring therapy in the preceding 2 years
- History of Barrett's esophagus
- Known history of sliding hiatal hernia ≥4 cm in the last 3 years
- Known history of erosive esophagitis Grade C or D (LA classification) in the past 5 years
- History of gastroparesis
- History of fibromyalgia, epilepsy, endometriosis
- Other medical conditions/medications that would interfere with subject safety or data collection in the opinion of the PI
- Uncontrolled diabetes mellitus, defined as HbA1c \> 7.5%
- Esophageal or gastric varices or esophageal peptic stricture
- Severe dysphagia
- Pregnant women or women intending to become pregnant during the trial period
- Having any implanted electrical device (e.g. sacral nerve stimulation, brain stimulator, others)
- Para-esophageal hiatal hernia
- Obesity, defined as BMI\>32
- Umbilical hernia \>3cm
- Past usage experience with the study device
- Those currently enrolled in any other interventional clinical study
- Inability to sign the informed consent
- Inability to understand and fill the reports and questionnaires included in the study
- Inability to follow the study requisites
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 22 and 75 years old?
Where in United States
Also in 1 other country, 4 sites
- Division of Gastroenterology & Hepatology Feinberg School of Medicine Northwestern UniversityChicago, United StatesContact: Ofer Z Fass, MDNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this research is to evaluate the safety and effectiveness of the eGERD device, which is a novel device for treating Gastroesophageal Reflux Disease (GERD).
Read full original descriptionShow less
The main questions this research aims to answer are:
1. Does the eGERD device reduce acidity in the esophagus? 2. Does the eGERD device reduce GERD symptoms such as heartburn and regurgitation? 3. What medical problems do participants have when using the eGERD device?
To assess the acidity in the esophagus, a wireless standard-of-care capsule called Bravo will be placed in the participants esophagus (throat) for several days.
To assess GERD symptoms, participants will be requested to report symptoms they experience using a smartphone application.
Researchers will compare a real version of the eGERD device to a sham version (a look-alike device that has no therapeutic effect) to see if the eGERD device is effective in treating GERD.
The 2 groups in the trial
- ActiveTreatment being tested
Participants in the active arm will be using a functional version of the investigational device for 28 days.
Treatment: eGERD device
- ControlSham treatment, for comparison
Participants in the control arm will be using a sham version of the investigational device for 28 days.
Treatment: eGERD_Sham
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effect of Non-Invasive Electrical Stimulation Therapy on Gastroesophageal Reflux Disease (GERD)
- Criteria questions
- Built from NCT06613438, who can take part
- Record updated
- 23 June 2026